Tango Therapeutics, Inc.
TNGX
Rangering i aksjer
#4544
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Aksjekurs
$27.18
Sist synkronisert: 2026-07-31
Markedsverdi
$3.38B
Endring (1 dag)
-1.41%
Endring (1 år)
202.34%
Land
US
Handel Tango Therapeutics, Inc. (TNGX)
Kategori
Healthcare
P/S-forhold for Tango Therapeutics, Inc. (TNGX)
P/S-forhold per October 2026 TTM: 67.14
Ifølge Tango Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 67.14. Ved slutten av 2023 hadde selskapet et P/S-forhold på 25.63.
P/S-historikk for Tango Therapeutics, Inc. fra 2019 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 67.14 | 737.15% |
| 2024 | 8.02 | -68.70% |
| 2023 | 25.63 | 0.08% |
| 2022 | 25.61 | 39.62% |
| 2021 | 18.34 | -61.56% |
| 2020 | 47.71 | 1,179.46% |
| 2019 | 3.73 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | -85.07% |
US
|
|
| 40.55 | -39.60% |
US
|
|
| 3.96 | -94.10% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -84.89% |
NL
|
